Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM13PQW)

Drug Name
Rilmenidine Drug Info
Synonyms
Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid
Cross-matching ID
PubChem CID
68712
ChEBI ID
CHEMBL289480
CAS Number
CAS 54187-04-1
TTD Drug ID
D06OFS

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Pyrimidine metabolism 2.14 0.00e+0 40/56 (71.43%) TYMS;UCK2;CTPS1;...
DNA replication 2.04 0.00e+0 34/36 (94.44%) PCNA;POLE2;FEN1;...
Mitophagy -1.70 2.02e-2 56/68 (82.35%) BNIP3L;FOXO3;CSNK2A2;...
Apoptosis -1.73 1.94e-2 126/168 (75%) HRK;LMNA;TRAF1;...
Proteoglycans in cancer -1.74 1.86e-2 172/205 (83.9%) STAT3;ITPR1;PPP1CC;...
Pancreatic cancer -1.74 1.88e-2 75/76 (98.68%) TGFA;EGFR;BRAF;...
Protein digestion and absorption -1.75 1.58e-2 78/103 (75.73%) FXYD2;COL13A1;COL11A2;...
Legionellosis -1.76 1.65e-2 51/57 (89.47%) RELA;BCL2L13;HSPA1A;...
Type I diabetes mellitus -1.76 1.55e-2 38/43 (88.37%) CD86;IL2;HLA-DMB;...
Sulfur metabolism -1.76 1.61e-2 9/10 (90%) TST;ETHE1;PAPSS1;...
Osteoclast differentiation -1.76 1.62e-2 117/127 (92.13%) FCGR2B;CSF1R;RELB;...
Shigellosis -1.78 1.37e-2 180/246 (73.17%) ITPR1;ATG12;CUL1;...
Th17 cell differentiation -1.78 1.44e-2 95/107 (88.79%) STAT1;IL27RA;IKBKB;...
IL-17 signaling pathway -1.79 1.30e-2 84/94 (89.36%) JUN;CCL17;CSF2;...
Amoebiasis -1.79 1.37e-2 99/102 (97.06%) RAB5B;ACTN4;CTSG;...
Bladder cancer -1.80 1.29e-2 40/41 (97.56%) HBEGF;TYMP;MDM2;...
Th1 and Th2 cell differentiation -1.81 1.12e-2 80/92 (86.96%) STAT1;IKBKB;IFNGR2;...
Ferroptosis -1.81 1.19e-2 36/41 (87.8%) GCLM;ACSL4;ACSL1;...
Viral protein interaction with cytokine and cytokine re... -1.81 1.28e-2 84/100 (84%) TNFSF14;CCL25;CCL11;...
Focal adhesion -1.84 1.06e-2 180/201 (89.55%) RASGRF1;TNXB;COL9A2;...
Epithelial cell signaling in Helicobacter pylori infect... -1.85 1.03e-2 62/70 (88.57%) PTPN11;ATP6V1H;ATP6V0C;...
ECM-receptor interaction -1.86 8.74e-3 80/88 (90.91%) TNXB;COL9A2;COMP;...
Inflammatory bowel disease -1.89 8.24e-3 58/65 (89.23%) IL4;IL22;HLA-DQB1;...
VEGF signaling pathway -1.90 9.16e-3 50/59 (84.75%) BAD;PLA2G4C;RAF1;...
Viral myocarditis -1.92 8.59e-3 53/60 (88.33%) HLA-DMB;PRF1;SGCG;...
Asthma -1.95 3.92e-3 25/31 (80.65%) IL4;HLA-DQB1;HLA-DOA;...
Natural killer cell mediated cytotoxicity -1.99 2.29e-3 99/131 (75.57%) PIK3R1;KLRD1;PTPN11;...
Kaposi sarcoma-associated herpesvirus infection -2.00 2.75e-3 172/193 (89.12%) ATG14;JUN;ANGPT2;...
Rheumatoid arthritis -2.03 3.43e-3 78/93 (83.87%) HLA-DMB;ATP6V1H;ATP6V0C;...
TNF signaling pathway -2.08 0.00e+0 103/112 (91.96%) CXCL5;PIK3R1;CREB5;...
Allograft rejection -2.21 0.00e+0 32/38 (84.21%) IL4;HLA-DQB1;HLA-DOA;...
Graft-versus-host disease -2.28 0.00e+0 32/42 (76.19%) CD86;KLRD1;IL2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 20uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H